Literature DB >> 23950621

Making no bones about it: Transcription factors in vertebrate skeletogenesis and disease.

Sumantra Chatterjee1, V Sivakamasundari, Wenqing Jean Lee, Hsiao Yun Chan, Thomas Lufkin.   

Abstract

Skeletogenesis is a complex multi-step process, which involves many genes and pathways. The tightly regulated interplay between these genes in these pathways ensures a correct and timely organogenesis and it is imperative that we have a fair understanding of the major genes and gene families involved in the process. This review aims to give a deeper insight into the roles of 3 major transcription factor families involved in skeleton formation: Sox, Runx and Pax and to look at the human skeleotogenic phenotypes associated with mutations in these genes.

Entities:  

Keywords:  Pax; Runx; Sox; microRNAs; skeletogenesis

Year:  2012        PMID: 23950621      PMCID: PMC3742036     

Source DB:  PubMed          Journal:  Trends Dev Biol        ISSN: 0972-8422


  67 in total

1.  The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage.

Authors:  Toshiyuki Ikeda; Satoru Kamekura; Akihiko Mabuchi; Ikuyo Kou; Shoji Seki; Tsuyoshi Takato; Kozo Nakamura; Hiroshi Kawaguchi; Shiro Ikegawa; Ung-il Chung
Journal:  Arthritis Rheum       Date:  2004-11

Review 2.  Distinct roles of Sox5, Sox6, and Sox9 in different stages of chondrogenic differentiation.

Authors:  Toshiyuki Ikeda; Hiroshi Kawaguchi; Satoru Kamekura; Naoshi Ogata; Yoshiyuki Mori; Kozo Nakamura; Shiro Ikegawa; Ung-il Chung
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 3.  Role of Runx proteins in chondrogenesis.

Authors:  Carolina A Yoshida; Toshihisa Komori
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2005       Impact factor: 1.807

Review 4.  Transcriptional networks controlling skeletal development.

Authors:  Christine Hartmann
Journal:  Curr Opin Genet Dev       Date:  2009-10-14       Impact factor: 5.578

5.  Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes.

Authors:  Peter Dy; Weihuan Wang; Pallavi Bhattaram; Qiuqing Wang; Lai Wang; R Tracy Ballock; Véronique Lefebvre
Journal:  Dev Cell       Date:  2012-03-13       Impact factor: 12.270

6.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

7.  NFAT and Osterix cooperatively regulate bone formation.

Authors:  Takako Koga; Yuichi Matsui; Masataka Asagiri; Tatsuhiko Kodama; Benoit de Crombrugghe; Kazuhisa Nakashima; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2005-07-24       Impact factor: 53.440

Review 8.  Aberrant Pax1 and Pax9 expression in Jarcho-Levin syndrome: report of two Caucasian siblings and literature review.

Authors:  Sergei I Bannykh; Shawn Clark Emery; Josef-Karl Gerber; Kenneth L Jones; Kurt Benirschke; Eliezer Masliah
Journal:  Am J Med Genet A       Date:  2003-07-15       Impact factor: 2.802

9.  Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation.

Authors:  Do Y Soung; Yufeng Dong; YongJun Wang; Michael J Zuscik; Edward M Schwarz; Regis J O'Keefe; Hicham Drissi
Journal:  J Bone Miner Res       Date:  2007-08       Impact factor: 6.741

10.  Targeted disruption of Pax1 defines its null phenotype and proves haploinsufficiency.

Authors:  B Wilm; E Dahl; H Peters; R Balling; K Imai
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  2 in total

1.  MiR-3960 binding sites with mRNA of human genes.

Authors:  Anatoly Ivashchenko; Olga Berillo; Anna Pyrkova; Raigul Niyazova; Shara Atambayeva
Journal:  Bioinformation       Date:  2014-07-22

Review 2.  High Fidelity of Mouse Models Mimicking Human Genetic Skeletal Disorders.

Authors:  Robert Brommage; Claes Ohlsson
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-04       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.